Anida Pharma
  • About Us
  • Our Science
  • Pipeline
  • News
  • Contact
Select Page

Per Gjorstrup

By: jonadmin|Published on: Aug 4, 2023|Categories: Management|

Recent Posts

  • Anida Pharma announces that FDA has granted orphan drug status to AP-001 for the treatment of neurotrophic keratopathy
  • Anida Pharma announces positive Pre-IND meeting with the FDA to set the path for clinical development of AP-001 for the treatment of retinopathy of prematurity
  • Anida Pharma announces European Orphan Drug Designation for AP-001
  • Anida Pharma granted rare pediatric disease designation for AP-001 for the prevention of retinopathy of prematurity (ROP)
  • Anida Pharma announces that FDA has granted AP-001 as a drug “for Rare Pediatric Disease” for the treatment of retinopathy of prematurity

Recent Comments

  1. A WordPress Commenter on Anida Pharma announces European Orphan Drug Designation for AP-001

Copyright © 2026 Anida Pharma